Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
Original Article
B.C. Cho, S. Lu, E. Felip, A.I. Spira, N. Girard, J.-S. Lee, S.-H. Lee, Y. Ostapenko, P. Danchaivijitr, B. Liu, A. Alip, E. Korbenfeld, J.M. Dias, B. Besse, K.-H. Lee, H. Xiong, S.-H. How, Y. Cheng, G.-C. Chang, H. Yoshioka, J.C.-H. Yang, M. Thomas, D. Nguyen, S.-H.I. Ou, S. Mukhedkar, K. Prabhash, M. D’Arcangelo, J. Alatorre-Alexander, J.C.V. Limón, S. Alves, D. Stroyakovskiy, M. Peregudova, M.A. Şendur, O. Yazici, R. Califano, V.G. Calderón, F.d. Marinis, A. Passaro, S.-W. Kim, S.M. Gadgeel, J. Xie, T. Sun, M. Martinez, M. Ennis, E. Fennema, M. Daksh, D. Millington, I. Leconte, R. Iwasawa, P. Lorenzini, M. Baig, S. Shah, J.M. Bauml, S.M. Shreeve, S. Sethi, R.E. Knoblauch, and H. Hayashi
N Engl J Med 2024;391:1486-1498
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation